81 related articles for article (PubMed ID: 18714320)
1. What's needed for personalized therapy in smoking cessation.
Epstein RS
Clin Pharmacol Ther; 2008 Sep; 84(3):309-10. PubMed ID: 18714320
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
[TBL] [Abstract][Full Text] [Related]
3. The total lifetime health cost savings of smoking cessation to society.
Rasmussen SR; Prescott E; Sørensen TI; Søgaard J
Eur J Public Health; 2005 Dec; 15(6):601-6. PubMed ID: 16014659
[TBL] [Abstract][Full Text] [Related]
4. One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services.
Bauld L; Boyd KA; Briggs AH; Chesterman J; Ferguson J; Judge K; Hiscock R
Nicotine Tob Res; 2011 Feb; 13(2):135-45. PubMed ID: 21196451
[TBL] [Abstract][Full Text] [Related]
5. Value to smokers of improved cessation products: evidence from a willingness-to-pay survey.
Busch S; Falba T; Duchovny N; Jofre-Bonet M; O'Malley S; Sindelar J
Nicotine Tob Res; 2004 Aug; 6(4):631-9. PubMed ID: 15370159
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
Boyd KA; Briggs AH
Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
[TBL] [Abstract][Full Text] [Related]
7. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
Menzin J; Lines LM; Marton J
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):257-64. PubMed ID: 19527098
[TBL] [Abstract][Full Text] [Related]
8. [Predictors of smoking cessation in group-based behavioral intervention programme--research findings in 2001-2007].
Broszkiewicz M; Sobala W; Drygas W
Przegl Lek; 2008; 65(10):634-40. PubMed ID: 19189567
[TBL] [Abstract][Full Text] [Related]
9. Experts' agreement on the relative effectiveness of 29 smoking reduction strategies.
Paul CL; Sanson-Fisher RW
Prev Med; 1996; 25(5):517-26. PubMed ID: 8888319
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of varenicline for smoking cessation.
Keiding H
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
[TBL] [Abstract][Full Text] [Related]
11. Web programs can be helpful, cost-effective way to stop smoking.
Mayo Clin Womens Healthsource; 2009 Dec; 13(12):3. PubMed ID: 19881446
[No Abstract] [Full Text] [Related]
12. An appraisal of smoking cessation aids.
Mundey K
Curr Opin Pulm Med; 2009 Mar; 15(2):105-12. PubMed ID: 19532024
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation.
Weimer DL; Vining AR; Thomas RK
Health Econ; 2009 Feb; 18(2):181-202. PubMed ID: 18566968
[TBL] [Abstract][Full Text] [Related]
14. A critical review of the arguments for insurance coverage for smoking-cessation therapies.
Chang CF
Manag Care; 2001 May; 10(5):62-5. PubMed ID: 11392730
[TBL] [Abstract][Full Text] [Related]
15. Telephone recruitment into a randomized controlled trial of quitline support.
Tzelepis F; Paul CL; Walsh RA; Wiggers J; Knight J; Lecathelinais C; Daly J; Neil A; Girgis A
Am J Prev Med; 2009 Oct; 37(4):324-9. PubMed ID: 19765505
[TBL] [Abstract][Full Text] [Related]
16. Modelling the health benefits of smoking cessation in Japan.
Avila-Tang E; Apelberg BJ; Yamaguchi N; Katanoda K; Sobue T; Samet JM
Tob Control; 2009 Feb; 18(1):10-7. PubMed ID: 18728096
[TBL] [Abstract][Full Text] [Related]
17. Nicotine dependence, psychological distress and personality traits as possible predictors of smoking cessation. Results of a double-blind study with nicotine patch.
Cosci F; Corlando A; Fornai E; Pistelli F; Paoletti P; Carrozzi L
Addict Behav; 2009 Jan; 34(1):28-35. PubMed ID: 18804918
[TBL] [Abstract][Full Text] [Related]
18. Progressive reduction using nicotine gum as a prelude to quitting.
Jiménez-Ruiz CA; Ulibarri MM; Besada NA; Guerrero AC; Garcia AG; Cuadrado AR
Nicotine Tob Res; 2009 Jul; 11(7):847-50. PubMed ID: 19443787
[TBL] [Abstract][Full Text] [Related]
19. Are cost-inclusive evaluations worth the effort?
Herman PM; Avery DJ; Schemp CS; Walsh ME
Eval Program Plann; 2009 Feb; 32(1):55-61. PubMed ID: 18977533
[TBL] [Abstract][Full Text] [Related]
20. Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases.
Quaak M; van Schayck CP; Knaapen AM; van Schooten FJ
Mutat Res; 2009 Jul; 667(1-2):44-57. PubMed ID: 19028511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
